Because many of the adverse events that were most commonly reported are associated with hereditary angioedema, "we could not separate whether this was due to drug effect or due to the attack," Dr. Lumry said.
The mean age of patients in the study’s different arms ranged from 36 to 50 years. Most of the patients were women, and most were white.
The study was funded by Shire, which is developing icatibant. Dr. Lumry has been a consultant or speaker for, or received research grants from, Shire, CSL Behring, Dyax, Pharming, and ViroPharma.